Edward Genton, M.D. (Associate); Phillip S. Wolf, M.D. (Associate)
This content is PDF only. Please click on the PDF icon to access.
Thrombolytic therapy with the plasminogen activator, urokinase (UK), was evaluated in 13 patients with angiographically confirmed bilateral massive pumonary thromboembolism. UK was administered intravenously for 8 to 12 hr at a rate of 1,500 to 2,000 CTA units/lb per hour. In group 1 (five patients) all symptoms occurred within 2 weeks before UK with fresh emboli within 72 hr. Average mean pulmonary artery pressure equaled 38 mm Hg. Each had marked symptomatic blood gas and angiographic improvement after UK, and mean pulmonary artery pressure fell to 24 mm Hg. Group 2 (four patients) had symptoms longer than 2 weeks, plus
Genton E, Wolf PS. Thrombolytic Therapy with Urokinase in Pulmonary Thromboembolism.. Ann Intern Med. ;68:1186. doi: 10.7326/0003-4819-68-5-1186_1
Download citation file:
Published: Ann Intern Med. 1968;68(5):1186.
Pulmonary Embolism, Pulmonary/Critical Care, Venous Thromboembolism.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use